The Jackson Laboratory and AbTherx Announce Partnership to Enhance Therapeutic Antibody Discovery
The Jackson Laboratory and AbTherx Announce Partnership to Enhance Therapeutic Antibody Discovery
BAR HARBOR, Maine and MOUNTAIN VIEW, Calif., May 10, 2024 /PRNewswire/ -- The Jackson Laboratory (JAX), an independent, nonprofit biomedical research organization, and AbTherx, an innovator in biotechnology, announced a strategic partnership to develop and commercialize cutting-edge tools to expedite antibody discovery and derisk the development of vital new therapies. This collaboration will include co-development activities and leverages JAX's extensive experience in model research and AbTherx's Atlas Mouse platform to address critical challenges facing drug developers of all sizes.
緬因州巴爾港和加利福尼亞州山景城，2024年5月10日 /PRNewswire/ — 獨立的非營利性生物醫學研究組織傑克遜實驗室（JAX）和生物技術創新者AbtherX宣佈建立戰略合作伙伴關係，開發和商業化尖端工具，以加快抗體發現，降低重要新療法開發的風險。這種合作將包括共同開發活動，並利用JAX在模型研究方面的豐富經驗和AbtherX的Atlas 鼠標平台可應對各種規模的藥物開發商面臨的關鍵挑戰。
The Atlas Mouse technologies are engineered to leverage in vivo antibody selection and maturation processes for the creation of human antibodies and are specifically designed to overcome the limitations of historical antibody discovery technologies by offering enhanced speed, diversity, developability, and affinity. Such traits are essential for developing viable lead candidates more swiftly than traditional methods currently allow.
阿特拉斯 小鼠技術經過精心設計，旨在利用體內抗體選擇和成熟過程來製造人體抗體，專爲通過提高速度、多樣性、可開發性和親和力來克服歷史抗體發現技術的侷限性而設計。這些特徵對於比目前傳統方法所允許的更快地開發出可行的潛在候選人至關重要。
JAX will also become the exclusive distributor of select AtlasMouse models, including AbTherx's Full Human Diversity Mouse for monoclonal antibody development as well as the Binary Fixed Light Chain Mouse for bispecific and multispecific antibody development. JAX and AbTherx are additionally exploring opportunities to develop and distribute future models to expand on this existing suite of innovative tools.
JAX 還將成爲精選 Atlas 的獨家分銷商小鼠模型，包括用於單克隆抗體開發的 AbtherX 全人類多樣性小鼠以及用於雙特異性和多特異性抗體開發的二元固定輕鏈小鼠。JAX 和 AbtherX 還在探索開發和分發未來模型的機會，以擴展這套現有的創新工具。
"By combining JAX's expertise in high-quality mouse models with the innovative capabilities of our Atlas Mouse platform, we are setting new industry standards," said Justin Mika, CEO of AbTherx. "This collaboration not only enhances our ability to create additional impactful technologies but also ensures that these advancements are within reach of researchers and developers globally, fostering a new era of medical innovation."
“通過將JAX在高質量鼠標模型方面的專業知識與我們的Atlas的創新能力相結合 鼠標平台，我們正在設定新的行業標準。” AbtherX首席執行官賈斯汀·米卡說。“這種合作不僅增強了我們創造更多有影響力的技術的能力，而且還確保了這些進步觸手可及，從而推動了醫學創新的新時代。”
"Providing access to high-quality research tools is paramount at The Jackson Laboratory, and we are thrilled to extend our capabilities with innovative models that are pivotal for the creation of new therapeutics," said Mitchell Kennedy, Executive Vice President of The Jackson Laboratory and President of JAX Mice, Clinical & Research Services. "Our partnership with AbTherx is a natural synergy, combining our decades of expertise in mouse model development with their deep knowledge in antibody discovery. Together, we are not only enhancing the tools available to researchers but also accelerating the pace at which impactful treatments can reach patients worldwide."
傑克遜實驗室執行副總裁兼JAX小鼠、臨床與研究服務總裁米切爾·肯尼迪表示：“在傑克遜實驗室，提供獲得高質量研究工具的途徑至關重要，我們很高興能夠通過對開發新療法至關重要的創新模型來擴展我們的能力。”“我們與AbtherX的合作是一種自然的協同作用，將我們在小鼠模型開發方面數十年的專業知識與他們在抗體發現方面的深厚知識相結合。我們共同努力，不僅增強了可供研究人員使用的工具，還加快了向全球患者提供有影響力的治療的步伐。”
An early access program is set to launch in the second half of the year, during which time drug developers are invited to test and evaluate these groundbreaking platforms. For more details or to participate in the early access program, please contact JAX at [email protected].
一項搶先體驗計劃定於下半年啓動，在此期間，藥物開發商將被邀請測試和評估這些開創性的平台。欲了解更多詳情或參與搶先體驗計劃，請通過 [email protected] 與 JAX 聯繫。
About The Jackson Laboratory
關於傑克遜實驗室
The Jackson Laboratory is an independent, nonprofit biomedical research institution with a National Cancer Institute-designated Cancer Center and nearly 3,000 employees in locations across the United States, Japan, and China. Its mission is to discover precise genomic solutions for disease and empower the global biomedical community in the shared quest to improve human health. For more information, please visit .
傑克遜實驗室是一家獨立的非營利性生物醫學研究機構，擁有國家癌症研究所指定的癌症中心，在美國、日本和中國各地有近 3,000 名員工。其使命是發現疾病的精確基因組解決方案，並賦予全球生物醫學界權力，共同尋求改善人類健康。欲了解更多信息，請訪問。
About AbTherx
關於 AbtherX
AbTherx is advancing medicine with revolutionary technologies that accelerate and enable therapeutic antibody discovery. Through an exclusive partnership with Gilead Sciences, AbTherx has released Atlas Mice, a suite of novel transgenic technologies designed for unmatched performance and FTO. For over 20 years, AbTherx's passionate, innovative, and collaborative team has pushed the boundaries of antibody discovery technologies, leading to over 1,000 successful antibody discovery campaigns and 13 marketed therapeutics. AbTherx's industry-leading team creates transformative solutions to overcome the most demanding challenges in delivering innovative medicines. Committed to making its technologies accessible to all, AbTherx offers flexible partnering models that meet the needs of drug developers of all sizes. For more information, please visit .
AbtherX 正在通過革命性技術推動醫學發展，這些技術可以加速和促進治療性抗體的發現。通過與吉利德科學的獨家合作，abtherX 發佈了 Atlas 小鼠，一套專爲無與倫比的性能和FTO而設計的新型轉基因技術。20多年來，AbtherX充滿激情、富有創新精神和協作精神的團隊突破了抗體發現技術的界限，成功開展了1,000多項抗體發現活動和13種上市療法。AbtherX 行業領先的團隊創造了變革性解決方案，以克服在交付創新藥物方面最嚴峻的挑戰。AbtherX 致力於讓所有人都能使用其技術，提供靈活的合作模式，以滿足各種規模的藥物開發商的需求。欲了解更多信息，請訪問。
SOURCE The Jackson Laboratory
來源：傑克遜實驗室
譯文內容由第三人軟體翻譯。